hBD-3(human beta-defensin-3)

General Information


DRACP ID  DRACP01056

Peptide Name   hBD-3(human beta-defensin-3)

Sequence  GIINTLQKYYCRVRGGRCAVLSCLPKEEQIGKCSTRGRKCCRRKK

Sequence Length  45

UniProt ID  Not available

PubChem CID  Not available

Origin  Homo sapiens

Type  Native peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma 0% Killing=40 µg/ml MTT assay 2h 1
A549 Lung adenocarcinoma Carcinoma 30% Killing=40 µg/ml MTT assay 2h 1

Hemolytic Activity  Human erythrocytes: 0% Hemolysis=40 µg/ml

Normal (non-cancerous) Cytotoxicity  Vero cells: 20% Killing=40 µg/ml

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial; Antifungal



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01056

Helicity  Not available

Linear/Cyclic  Cyclic

Disulfide/Other Bond  Cys11<---Cys40; Cys18<--->Cys33; Cys23<---Cys41

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C216H377N75O59S6

Absent amino acids  DFHMW

Common amino acids  R

Mass  594620

Pl  10.63

Basic residues  13

Acidic residues  2

Hydrophobic residues  9

Net charge  11

Boman Index  -12951

Hydrophobicity  -70

Aliphatic Index  67.11

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  3355

Absorbance 280nm  76.25

Polar residues  18

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 34025617

Title  A Chimeric Cationic Peptide Composed of Human β-Defensin 3 and Human β-Defensin 4 Exhibits Improved Antibacterial Activity and Salt Resistance

Doi 10.3389/fmicb.2021.663151

Year  2021

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.